4.8 Article

Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 11, 页码 4446-4461

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI57682

关键词

-

向作者/读者索取更多资源

Systemic inflammatory response syndrome (SIRS) is a potentially lethal condition, as it can progress to shock, multi-organ failure, and death. It can be triggered by infection, tissue damage, or hemorrhage. The role of tissue injury in the progression from SIRS to shock is incompletely understood. Here, we show that treatment of mice with concanavalin A (ConA) to induce liver injury triggered a G-CSF-dependent hepatic infiltration of CD11b(+)Gr-1(+)Ly6G(+)Ly6C(+) immature myeloid cells that expressed the orphan receptor myeloid DAP12-associated lectin-1 (MDL-1; also known as CLEC5A). Activation of MDL-1 using dengue virus or an agonist MDL-1-specific antibody in the ConA-treated mice resulted in shock. The MDL-1(+) cells were pathogenic, and in vivo depletion of MDL-1(+) cells provided protection. Triggering MDL-1 on these cells induced production of NO and TNF-alpha, which were found to be elevated in the serum of treated mice and required for MDL-1-induced shock. Surprisingly, MDL-1-induced NO and TNF-alpha production required eNOS but not iNOS. Activation of DAP12, DAP10, Syk, PI3K, and Akt was critical for MDL-1-induced shock. In addition, Akt physically interacted with and activated eNOS. Therefore, triggering of MDL-1 on immature myeloid cells and production of NO and TNF-alpha may play a critical role in the pathogenesis of shock. Targeting the MDL-1/Syk/PI3K/Akt/eNOS pathway represents a potential new therapeutic strategy to prevent the progression of SIRS to shock.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone, Anthony W. Tolcher

CLINICAL CANCER RESEARCH (2015)

Article Biotechnology & Applied Microbiology

In-situ tumor vaccination: Bringing the fight to the tumor

Robert H. Pierce, Jean S. Campbell, Sara I. Pai, Joshua D. Brody, Holbrook E. K. Kohrt

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)

Article Biochemistry & Molecular Biology

Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters

C. Burkart, A. Mukhopadhyay, S. A. Shirley, R. J. Connolly, J. H. Wright, A. Bahrami, J. S. Campbell, R. H. Pierce, D. A. Canton

GENE THERAPY (2018)

Article Immunology

Interleukin-23 is sufficient to induce rapid de novo legut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells

I. H. Chan, R. Jain, M. S. Tessmer, D. Gorman, R. Mangadu, M. Sathe, F. Vives, C. Moon, E. Penaflor, S. Turner, G. Ayanoglu, C. Chang, B. Basham, J. B. Mumm, R. H. Pierce, J. H. Yearley, T. K. McClanahan, J. H. Phillips, D. J. Cua, E. P. Bowman, R. A. Kastelein, D. LaFace

MUCOSAL IMMUNOLOGY (2014)

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio J. Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce, David A. Elashoff, Caroline Robert, Antoni Ribas

NATURE (2014)

Editorial Material Immunology

Killer T cells find meaningful encounters through iMATEs

Ian N. Crispe, Robert H. Pierce

NATURE IMMUNOLOGY (2013)

Article Biochemistry & Molecular Biology

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

Jonathan P. Sherlock, Barbara Joyce-Shaikh, Scott P. Turner, Cheng-Chi Chao, Manjiri Sathe, Jeff Grein, Daniel M. Gorman, Edward P. Bowman, Terrill K. McClanahan, Jennifer H. Yearley, Gerard Eberl, Christopher D. Buckley, Robert A. Kastelein, Robert H. Pierce, Drake M. LaFace, Daniel J. Cua

NATURE MEDICINE (2012)

Article Biochemistry & Molecular Biology

Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy

Anandaroop Mukhopadhyay, Jocelyn Wright, Shawna Shirley, David A. Canton, Christoph Burkart, Richard J. Connolly, Jean S. Campbell, Robert H. Pierce

GENE THERAPY (2019)

Article Oncology

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma

Ingunn M. Stromnes, Adam L. Burrack, Ayaka Hulbert, Patrick Bonson, Cheryl Black, J. Scott Brockenbrough, Jackson F. Raynor, Ellen J. Spartz, Robert H. Pierce, Philip D. Greenberg, Sunil R. Hingorani

CANCER IMMUNOLOGY RESEARCH (2019)

Article Oncology

Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses

Samantha K. Greaney, Alain P. Algazi, Katy K. Tsai, Kathryn T. Takamura, Lawrence Chen, Christopher G. Twitty, Li Zhang, Alan Paciorek, Robert H. Pierce, Mai H. Le, Adil Daud, Lawrence Fong

CANCER IMMUNOLOGY RESEARCH (2020)

Review Oncology

The Liver-Immunity Nexus and Cancer Immunotherapy

James C. Lee, Michael D. Green, Laura A. Huppert, Christine Chow, Robert H. Pierce, Adil Daud

Summary: Liver metastases have a significant impact on the effectiveness of immune checkpoint inhibitors in patients with solid-tumor malignancies. Multiple clinical and translational studies have shown that liver metastasis leads to systemic immune suppression through the generation of suppressive macrophages and activation of regulatory T-cells. Various interventions, such as radiation therapy and combination checkpoint blockade, have been reported to address liver immune suppression.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

Peter H. Goff, Laura Riolobos, Bonnie J. LaFleur, Matthew B. Spraker, Y. David Seo, Kimberly S. Smythe, Jean S. Campbell, Robert H. Pierce, Yuzheng Zhang, Qianchuan He, Edward Y. Kim, Stephanie K. Schaub, Gabrielle M. Kane, Jose G. Mantilla, Eleanor Y. Chen, Robert Ricciotti, Matthew J. Thompson, Lee D. Cranmer, Michael J. Wagner, Elizabeth T. Loggers, Robin L. Jones, Erin Murphy, Wendy M. Blumenschein, Terrill K. McClanahan, Jon Earls, Kevin C. Flanagan, Natalie A. LaFranzo, Teresa S. Kim, Seth M. Pollack

Summary: This study aims to characterize the changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy and provides insights for neoadjuvant immunotherapy trial design. The results show that neoadjuvant therapy significantly increases immune cell infiltration in the tumor and affects the expression of immune-related genes and cytokines. These findings inform the incorporation of immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

Robert H. I. Andtbacka, Yan Wang, Robert H. Pierce, Jean S. Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, Katie Niland, Robert D. Arbeit, Sudha Parasuraman, Kris Bickley, Cecilia C. S. Yeung, Lauri D. Aicher, Kimberly S. Smythe, Lu Gan

Summary: The study found that treatment with single-agent mavorixafor can increase CD8+ T-cell infiltration, granzyme B signal, antigen presentation machinery, and both tumor inflammatory signature (TIS) and IFNγ gene expression signature scores. When mavorixafor was combined with pembrolizumab, the increases in the key serum cytokines CXCL9 and CXCL10 were further enhanced. Reported adverse events included diarrhea, fatigue, maculopapular rash, and dry eye, all of which were ≤ grade 3.

CANCER RESEARCH COMMUNICATIONS (2022)

Meeting Abstract Oncology

Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.

Adil Daud, Alain Patrick Algazi, Michelle T. Ashworth, Lawrence Fong, Jera Lewis, Stephen E. Chan, Michael Buljan, Manuel Alberto Molina, Kathryn Toshimi Takamura, Tuan Tu Diep, Richard Heller, Robert H. Pierce, Shailender Bhatia

JOURNAL OF CLINICAL ONCOLOGY (2014)

Meeting Abstract Medicine, General & Internal

Interleukin 23 is critical in the pathogenesis of spondyloarthropathy and acts on a novel population of interleukin 23R+entheseal resident cells

Jonathan P. Sherlock, Barbara Joyce-Shaikh, Scott Turner, Manjiri Sathe, Jeff Grein, Daniel M. Gorman, Edward P. Bowman, Terrill K. McClanahan, Jennifer Yearley, Christopher D. Buckley, Robert A. Kastelein, Robert H. Pierce, Drake LaFace, Daniel J. Cua

LANCET (2013)

暂无数据